Loading patent…
AssigneePurdue Pharma L.P.
InventorsArie L. GUTMAN, Marina Etinger, Irina Fedotev, Ram Khanolkar, Gennady A. Nisnevich, Boris Pertsikov, Igor Rukhman, Boris Tishin
Estimating the term…
Methods for making trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ9-tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-Δ9)-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(−)-Δ9-tetrahydrocannabinol based on the total amount of trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(−)-Δ9-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.
A trans-(−)-Δ9-tetrahydrocannabinol composition comprising at least 99.0% by weight of trans-(−)-Δ9-tetrahydrocannabinol and less than 0.05% of Δ9-tetrahydrocannabinol acid based on the total amount of cannabinoids.
A trans-(+)-Δ9-tetrahydrocannabinol composition comprising at least about 98% by weight of trans-(+)-Δ9-tetrahydrocannabinol based on the total amount of cannabinoids.
A method for preparing a composition comprising trans-(−)-Δ9-tetrahydrocannabinol, comprising:
A method for preparing a composition comprising trans-(+)-Δ9-tetrahydrocannabinol, comprising:
A composition comprising trans-(−)-Δ9-tetrahydrocannabinol, trans-(+)-Δ9-tetrahydrocannabinol, a water-immiscible organic solvent, a water-miscible alcohol, water, and an alkali metal hydroxide, wherein the trans-(−)-Δ9-tetrahydrocannabinol is present in an amount from 0.75 to 1.25 molar equivalents per molar equivalent trans-(+)-≢9-tetrahydrocannabinol.
Dependencies are inferred from the claim text.